Our top pick for
Building a portfolio
Insmed Incorporated is a biotechnology business based in the US. Insmed Incorporated shares (INSM) are listed on the NASDAQ and all prices are listed in US Dollars. Insmed Incorporated employs 521 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$18.58 - $45.44|
|50-day moving average||$35.87|
|200-day moving average||$36.97|
|Wall St. target price||$53.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.09|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$164.4 million|
|Gross profit TTM||$124.5 million|
|Return on assets TTM||-21.55%|
|Return on equity TTM||-109.42%|
|Market capitalisation||$3.5 billion|
TTM: trailing 12 months
There are currently 8.8 million Insmed Incorporated shares held short by investors – that's known as Insmed Incorporated's "short interest". This figure is 2.5% up from 8.6 million last month.
There are a few different ways that this level of interest in shorting Insmed Incorporated shares can be evaluated.
Insmed Incorporated's "short interest ratio" (SIR) is the quantity of Insmed Incorporated shares currently shorted divided by the average quantity of Insmed Incorporated shares traded daily (recently around 1.2 million). Insmed Incorporated's SIR currently stands at 7.21. In other words for every 100,000 Insmed Incorporated shares traded daily on the market, roughly 7210 shares are currently held short.
However Insmed Incorporated's short interest can also be evaluated against the total number of Insmed Incorporated shares, or, against the total number of tradable Insmed Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Insmed Incorporated's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Insmed Incorporated shares in existence, roughly 90 shares are currently held short) or 0.1104% of the tradable shares (for every 100,000 tradable Insmed Incorporated shares, roughly 110 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Insmed Incorporated.
Find out more about how you can short Insmed Incorporated stock.
We're not expecting Insmed Incorporated to pay a dividend over the next 12 months.
Insmed Incorporated's shares were split on a 1:10 basis on 2 March 2011. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Insmed Incorporated shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Insmed Incorporated shares which in turn could have impacted Insmed Incorporated's share price.
Over the last 12 months, Insmed Incorporated's shares have ranged in value from as little as $18.58 up to $45.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Insmed Incorporated's is 2.3094. This would suggest that Insmed Incorporated's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey. .
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.